

Diabetes and Gene Editing

Cell based therapy for single mutation induced diabetes



GENE THERAPY COURSE – ISABELLA SAGGIO
2015-2016



SAPIENZA
UNIVERSITÀ DI ROMA

Monogenic Diabetes : Two types ⁽¹⁾



- Monogenic forms of pancreatic β -cell dysfunction include maturity-onset diabetes of the young (MODY) and neonatal diabetes.
- MODY is the most common form of inherited diabetes (constitutes 1-5% of all cases of diabetes in industrialized countries)

Symptoms and Features :

MODY

- High blood glucose, polyuria, polydipsia, fatigue
- Diagnosed with diabetes under the age of 25
- Parent with diabetes plus in two or more generations
- Not necessarily needing insulin.
- HNF1-alpha gene causes about 56 % of cases
- INS mutated in 4% of the cases


NEONATAL

- High blood glucose, polyuria, polydipsia
- Diagnosed with under the age of 6 months
- Possible development delay
- Rare
- Transient of permanent
- 50 % of people do not need insulin
- INS mutated in 16% of permanent neonatal diabetes

Our model : The MODY Mouse (2-3)



- C57BL/6 - *Ins2^{Akita}*/J Mouse




- Mutation on chromosome 7 in insulin 2 (*Ins2*) coding gene.

- Single point mutation :
TGC → TAC
Cysteine Tyrosine

- The mouse autosomal dominant mutation *Mody* develops hyperglycemia with notable pancreatic β -cell dysfunction.
- The mouse develop also, hypoinsulinemia, polydipsia, and polyuria with no obesity and insulinitis.


How ? The cell based strategy.




1

Generation of fibroblast derived iPSC cells


- Ectopic expression of Yamanaka's factors Myc, Oct4, Klf4, Sox2 in MODY mouse fibroblasts **AND** WT C57BL/6J mouse.



Pipeline from *Hongmei Lisa Li et al 2015* to check for stable, integration free iPSC clones ⁽⁴⁾




- Colony with stable karyotype
- Test for pluripotency markers, including Nanog Oct 3/4, TRA-1-60 and SSEA-5.



- Teratoma assay to test pluripotency

MODY - FiPS



Histological Examination




- Integration free clones assessment using qPCR.

* chose on Addgene for their Non-integrating and mammalian expression of mouse genes.

2


CRISPR/Cas9 mediated engineering ⁽⁵⁾

- The RNA guided nuclease Cas9 allows sequence specific double strand breaks.
- DNA repair via homology directed repair (HDR) permit genome editing.
- Require a Protospacer Adjacent Motif (PAM) sequence 5'-NGG-3' in the genome.
- Requires a DNA template sequence for HDR.
- Proved efficient in mouse iPSC and hiPSC⁽⁴⁾




2

CRISPR mediated correction via HDR in MODY mouse



4 Different sgRNA were tested using in vitro assay

In vitro Cas9 cleavage assay



N°4 selected for further experiments

➤ The sgRNAs were designed using Broad Institute website ⁽⁶⁾.



* Ins2 gene sequence obtained on NCBI website (Reference Sequence: NC_000073.6 : C57BL/6J chromosome 7, GRCm38.p3)

2


CRISPR machinery and Template delivery

- Use of the pSpCas9(BB)-2A-GFP (Addgene) recently and successfully used for knockout mESC generation ⁽⁷⁾
- Cloning of the guide RNA 4
- Use of 100 nt long oligonucleotides for HDR (Ultramer[®] Oligonucleotides IDT)

5' - CACCGGTAGAGGGAGCGAGTGC - 3'
3' - CCATCTCCCTCGCTCACGCAA - 5'



+



Coelectroporation in MODY FiPS cells *


- FACS for GFP positive cells



Commonly used and efficient in miPSC ⁽⁸⁾ and bovine iPSC ⁽⁹⁾

* WT FiPS cell were treated the same way but without plasmids and templates.

Selection of safely corrected cells



Deep Sequencing to control predicted off target (Cas-OFFinder). One potential with one mismatch within Chr 19 Position 1,8785,396 (Intron in Trpm6 gene)

Multiple Whole-genome analysis to select clones with low mutation load*

* The selected clone are called MODY FiSC cells for fibroblasts Induced Stem Corrected cells

3

Differentiation into functional pancreatic β cells


Stage specific
extracellular
markers for post-
step FACS ⁽⁸⁻¹¹⁾ :

CXCR4⁺

CD133⁺

GLUT2⁺ / CD133⁻

Multistep Process :




* WT FiPS cell were treated the same way and called WT FiPSC- β Cells .

In Vitro Assays : Glucose responsiveness & Insulin expression



Cell Sorting using for GLUT2⁺ / CD133⁻ cells

WT β cells




Glucose
2.5mM



Glucose
25mM



MODY FiPSC - β Cells




Glucose
2.5mM



Glucose
25mM



WT FiPS - β Cells



Glucose
2.5mM



Glucose
25mM




Insulin concentration in supernatant using Elisa to test insulin responsiveness

RT PCR on cells to test Insulin 1 and 2 expression after incubation with 2.5mM


In Vitro Results : Glucose responsiveness & Insulin expression

RT PCR




- Expression of insulin 1 and 2 in MODY FiPSC- β Cells and WT iPC- β Cells albeit at a lower level compared to WT β Cells.

Elisa Insulin




- The MODY iPSC differentiated Beta cells are sensitive to glucose concentration.

In Vivo Experiments



Same experiment in parallel but injecting WT FiPS- β Cell treated the same way but without correction.


In Vivo Results



Measurement using a
portable glucometer
(Roche)

- MODY iPSC derived β -cell regulates the glycemia after liver and kidney injection as well as WT iPS derived Beta cells.

In Vivo Results





**** : pvalue < 0.0001

*** : pvalue < 0.001



T- test comparing circulating insulin level to untreated MODY mice

Measurement using Elisa test.

- The mice show higher circulating insulin after transplantation compared to non treated albeit at a 10 times lower level than wildtype.




Kidney injected with MODY FiPSC-β cells



Liver injected with MODY FiPSC-β cells

- Expression of insulin and C-peptide in the kidney and in the liver. (H&E, diaminobenzidine⁽⁸⁾).

Long term safety



Same experiment in parallel but injecting WT FiPSC- β Cell treated the same way but without correction.

Discussion



- Gene editing possible in hiPSC ⁽⁴⁾
- Knockin & Knockout doable and reported for other diseases ⁽⁴⁾
- Feasible on other forms of MODY and neonatal diabetes
- Potentially useful for other illness like monogenic liver diseases
- Potential long term efficiency



- Improve Crispr safety using bioinformatics tools (Looking for unique sgRNA sequence) ⁽⁴⁾
- Challenges still remains for human β cell differentiation. ⁽¹⁰⁾
- Production of a larger amount of cells than for the mouse model
- **Long term safety at a human scale**
Use of a suicide genes before transplantation ?

Cost and Time



PhD Project (4 years) ~ 50 000\$

- MODY Mice + WT mice + Stabulation ~ 199\$ x 5 males + 25\$ x 5 WT females.
- Stabulation for the mice ~ 500\$ / months.
- Expression vectors (Addgene) : pCX-cMYC + CX-OXS-2A : 130 \$
- CRISPR Vector (Addgene) : pSpCas9(BB)-2A-GFP (PX458) : 65 \$
- Ultramer Oligonucleotide (IDT) : 78 - 172 \$
- Exome sequencing : 800 -1200 \$ times the number of clones tested.
- Multiple control sequencing : ~ 2000\$
- FACS antibodies : 8 x 200-300 \$ + respective isotype controls .
- Immunohistochemistry antibodies : 200-300\$ x Antibodies + secondary antibodies
- Ultra sensitive mouse Insulin ELISA kit (biorbyt): 580 \$ / plates
- Non evaluable costs includes routine lab experiments and trouble shootings.

References



- 1 - www.diabetes.org.uk
- 2 - Mathews CE; Langley SH; Leiter EH. 2002. New mouse model to study islet transplantation in insulin-dependent diabetes mellitus. *Transplantation* 73(8):1333-6
- 3 - Wang J; Takeuchi T; Tanaka S; Kubo SK; Kayo T; Lu D; Takata K; Koizumi A; Izumi T. 1999. A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. *J Clin Invest* 103(1):27-37.
- 4 - Hongmei Lisa Li, Naoko Fujimoto, Noriko Sasakawa, et al. Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9, *Stem Cell Reports*, Volume 4, Issue 1, 13 January 2015, Pages 143-154, ISSN 2213-6711
- 5 - F Ann Ran, Patrick D Hsu, Jason Wright et al. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013 November ; 8(11): 2281–2308. doi:10.1038/nprot.2013.143.
- 6 - <http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design>
- 7 - Wettstein R, Bodak M, Ciaudo C. Generation of a Knockout Mouse Embryonic Stem Cell Line Using a Paired CRISPR/Cas9 Genome Engineering Tool. *Methods Mol Biol*. 2016;1341:321-43. doi: 10.1007/7651_2015_213.
- 8 - Kilsoo Jeon, Hyejin Lim, Jung-Hyun Kim et al. Differentiation and Transplantation of Functional Pancreatic Beta Cells Generated from Induced Pluripotent Stem Cells Derived from a Type 1 Diabetes Mouse Model *STEM CELLS AND DEVELOPMENT* Volume 21, Number 14, 2012 DOI: 10.1089/scd.2011.0665
- 9 - Young Tae Heo, Xiaoyuan Quan, Yong Nan Xu et al. CRISPR/Cas9 Nuclease-Mediated Gene Knock-In in Bovine-Induced Pluripotent Cells. *STEM CELLS AND DEVELOPMENT* . SEPTEMBER 2014 DOI: 10.1089/scd.2014.0278
- 10 - Nina Quiskamp, Jennifer E. Bruin, Timothy J. Kieffer, Differentiation of human pluripotent stem cells into β -cells: Potential and challenges, *Best Practice & Research Clinical Endocrinology & Metabolism*, Available online 30 October 2015, ISSN 1521-690X
- 11 - Takuya Sugiyama, Ryan T. Rodriguez, Graeme W. McLean Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. *Proc Natl Acad Sci U S A*. 2007 Jan 2; 104(1): 175–180